AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02450786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Donepezil is started in patients with Parkinson's disease mild cognitive impairment with 5mg for 8 weeks followed by dose up to 10mg and then maintained for 40 weeks. Participants who are not tolerable to dose of 10mg due to any issues of adverse effects would be maintained with donepezil 5mg exclusively in remained period.
Study NCT02988232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sogyeonghwalhyeol-tang
Description: herbal extract
Study NCT02988232 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: extract powder with same appearance, odor and color as SGHH
Study NCT01018992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK561679
Description: GSK561679, oral administration, 350mg/day, 6 week administration
Study NCT01018992 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo, oral administration, 1 pill/day for 6 weeks
Study NCT02400749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: Apremilast tablets will be provided to sites in blister cards.~Patients will be provided a titration blister pack containing apremilast 10 mg, 20 mg and 30 mg at the Day 0 and week 16 visits (refer to section 6.1). Following the 6 day titration period (for Day 0 and week 16) blister packs will contain apremilast 30 mg bid or placebo bid.
Study NCT02400749 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Apremilast
Description: Apremilast tablets will be provided to sites in blister cards.~Patients will be provided a titration blister pack containing apremilast 10 mg, 20 mg and 30 mg at the Day 0 and week 16 visits (refer to section 6.1). Following the 6 day titration period (for Day 0 and week 16) blister packs will contain apremilast 30 mg bid or placebo bid.
Study NCT02400749 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets will be provided to sites in blister cards.
Study NCT02660086 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized nutrition feedback
Description: Automated personalized nutrition feedback about cafeteria food purchases (weekly); social norms and small financial incentives to promote healthy purchases (monthly)
Study NCT03647800 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: APVO436
Description: APVO436
Study NCT02499991 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: memory
Description: keep track of social events in diary for memory recall. Used by treatment group
Study NCT00785798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: 200mg to 400 mg twice daily on days 1-7
Study NCT00785798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Liposomal Doxorubicin (PLD), Doxil
Description: IV 30mg/m2 on day 3 of a 21-day cycle
Study NCT00051740 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Adaptation Therapy (CAT)
Study NCT00051740 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Minimal Environmental Supports (MES)
Study NCT01946256 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Study NCT01946256 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Erythromycin
Study NCT04254965 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music therapy
Description: Treatment including instrument playing, singing, lyrics modification/music organized play, listening to music and discussing each treatment process.
Study NCT04254965 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Music therapy
Description: Treatment including instrument playing, singing, lyrics modification/music organized play, listening to music and discussing each treatment process.
Study NCT04254965 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biosignal analysis
Description: Measurement of facial expression emotion recognition, electrodermal activity, heart rate variability, sleep pattern, blood pressure, and electromyogram.
Study NCT04254965 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biosignal analysis
Description: Measurement of facial expression emotion recognition, electrodermal activity, heart rate variability, sleep pattern, blood pressure, and electromyogram.
Study NCT04254965 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Biosignal analysis
Description: Measurement of facial expression emotion recognition, electrodermal activity, heart rate variability, sleep pattern, blood pressure, and electromyogram.
Study NCT01092689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PhiP
Description: 1 capsule of 84 micrograms; 15.6 micro-curies \[14C\]PhIP
Study NCT01262872 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Polio Sabin™
Description: Orally
Study NCT01262872 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: M-Vac™
Description: Intramuscular injection
Study NCT03782545 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cutera truSculpt Device
Description: The Cutera truSculpt Device uses radio frequency (RF) energy to provide topical heating for the purpose of elevating tissue temperature for the treatment of selected medical conditions, such as temporary reduction in the appearance of cellulite.
Study NCT00560209 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ONO-1101
Description: placebo for 1 minute IV
Study NCT00560209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-1101
Description: 0.06 mg/kg for 1 minute IV
Study NCT00560209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-1101
Description: 0.125 mg/kg for 1 minute IV
Study NCT00587171 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Patching
Description: 2 hours daily patching
Study NCT00587171 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Patching
Description: 2 hours daily patching
Study NCT00587171 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Near activities
Description: 30 minutes daily near activities at home
Study NCT00587171 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Near activities
Description: 30 minutes daily near activities at home
Study NCT00587171 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Active vision therapy
Description: 30 minutes of daily at-home active vision therapy and a weekly 45 minute in-office active vision therapy session
Study NCT00587171 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Control vision therapy
Description: 30 minutes of daily at-home control vision therapy and a weekly 45 minute in-office control vision therapy session
Study NCT02857686 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intravenous regional anaesthesia
Description: tourniquet over the arm and intravenous lidocaine with a dose of 4 mg/kg
Study NCT02888899 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biofeedback
Study NCT02888899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loperamide
Study NCT02888899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stool bulking agent (sterculia or ispaghula husk)
Study NCT02888899 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PTNS
Study NCT01578928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOM230
Study NCT02656108 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ommited controlled cord traction
Description: No controlled cord traction and no fundal pressure. placenta will be allowed to deliver physiologically
Study NCT02656108 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: controlled cord traction
Description: active management of third stage of labor in the form of uterine massage with controlled cord traction
Study NCT01733914 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture in the following acupoints on the contralateral side of pain site: Jiantong, Zhongzhu, Houxi, and Quchi. The patient will receive 5 treatments (each lasts 30 min) per week for four weeks.
Study NCT01733914 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Patients in the waiting list group received conventional orthopaedic therapy including physical exercise, heat or cold therapy. 50 mg diclofenac daily could be taken when the patient suffered from the pain. Injections or cortisone applications of any kind were not allowed.
Study NCT02857686 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: forearm IVRA
Description: tourniquet over the forearm and lidocaine with a dose of 1.5 mg/ kg
Study NCT02020200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MPH
Description: MPH dosage will be determined according to participants' body weight: dosage: 10 mg in case weight\<40 kg; 30 mg in case weight>90 kg; otherwise 20 mg.
Study NCT02020200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT00865033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin HCL Tablets, 1000 mg Sandoz
Study NCT00865033 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucophage 1000 mg
Study NCT01262872 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: M-Vac™
Description: Intramuscular injection
Study NCT01262872 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stamaril™
Description: Intramuscular injection
Study NCT01262872 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Stamaril™
Description: Intramuscular injection
Study NCT01599078 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Drug dosing is 3mcg/mm3 of artery treated with percutaneous revascularization. Drug will be administered via the TAPAS catheter and allowed to dwell for 5 minutes.
Study NCT01835158 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cabozantinib S-malate
Description: Given PO
Study NCT01835158 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01849211 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: rocuronium
Study NCT02037425 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: onabotulinumtoxinA
Description: BOTOX® (Formulation Number 9060X) contains 200 International Units (IU) of Clostridium botulinum Toxin Type A, reconstituted with 4 cc of normal saline providing 5 units per 0.1 cc. At visit 2, subjects will receive their first treatment at Day 29 (+/-3 days). All subjects will receive 155 U Botulinum Toxin Type A Purified Neurotoxin Complex administered at 31 fixed-site, fixed-dose injections across seven (7) specific head/neck muscle areas. Injections will be repeated at day 113 (+/- 3 days) and at day 197 (+/- 3 days).
Study NCT01599078 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline will be administered intra-arterially via the TAPAS catheter following percutaneous revascularization. The dwell time will be 5minutes.
Study NCT00402675 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Timing of percutaneous coronary intervention
Description: Immediate, early or selective invasive angiography
Study NCT02226237 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: group of pelvic floor exercises
Description: contraction of the pelvic floor muscles sustained for 5 seconds, hip adductors using pillow and elevation of the hip, 30 repetitions of each exercise
Study NCT01225250 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polydioxanone (PDS) plates
Description: 0.5 mm PDS Flexible Plate made of poly-p-dioxanone, an aliphatic polyester which is manufactured by polymerization of the monomer p-dioxanone. Polydioxanone is a resorbable material degraded by hydrolysis and has been successfully used for bone discontinuities and septal reconstruction.
Study NCT02226237 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: anal electrostimulation group
Description: The anal electrical stimulation protocol was performed by a physical therapist for seven weeks, twice per week, using the apparatus Dualpex 961 Uro® Quark, with frequency of 35 Hz, and the intensity determined according to the tolerance of the patient, lasting 20 minutes.
Study NCT01225250 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Caudal septal extension graft performed through endonasal rhinoplasty
Description: The caudal septal extension (CSE) graft is a common method used to alter tip projection, alar-columellar relationship, and nasolabial angle.5 However, it can be difficult to stabilize and straighten the CSE graft, especially when performed through an endonasal approach. Use of a polydioxanone plate would provide a scaffolding for the CSE graft and could allow for a technically easier and more predictable surgical procedure.
Study NCT01225250 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Caudal septal extension graft performed through endonasal rhinoplasty
Description: The caudal septal extension (CSE) graft is a common method used to alter tip projection, alar-columellar relationship, and nasolabial angle.5 However, it can be difficult to stabilize and straighten the CSE graft, especially when performed through an endonasal approach. Use of a polydioxanone plate would provide a scaffolding for the CSE graft and could allow for a technically easier and more predictable surgical procedure.
Study NCT01841684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anacetrapib
Description: 100 mg tablet orally, once daily for 12 weeks
Study NCT01841684 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for anacetrapib orally, once daily for 12 weeks
Study NCT00197444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDGP/5-FU combined with radiation
Description: Low-dose of Nedaplatin (CDGP) 10 mg/body/day was daily administered on day 1-5, 8-13, 15-19, 22-26 and 5-FU 500 mg/body/day was continuously administered on day 1-5, 8-13, 15-19, 22-26.
Study NCT00197444 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Fractionated external radiotherapy was performed from the first day of chemotherapy and a total dose of 50.4-66 Gy was delivered at the rate of 1.8-2.0 Gy per fraction.
Study NCT05147207 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Superpath Approach
Description: This is a minimally invasive surgical approach for THA.
Study NCT02793557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOL-005
Description: Intradermal injection of 50 μl solution
Study NCT02793557 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT06037577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM-101
Description: Anti-human CCL24 monoclonal antibody (CM-101)
Study NCT06037577 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator
Study NCT00033748 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: monoclonal antibody 11D10 anti-idiotype
Description: 2 mg intradermal injection q 14 days for 4 doses, then sub Q monthly for 4 months, following a 6-12 wk rest period after curative hepatic resection
Study NCT00033748 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: monoclonal antibody 3H1 Alu Gel
Description: 2 mg intradermal injection q 14 days for 4 doses, then sub Q monthly for 4 months, following a 6-12 wk rest period after curative hepatic resection
Study NCT04582851 — intervention group
Intervention type: OTHER
Intervention: some risk factors correlated with TMD
Description: exposure factors causing TMD
Study NCT00002524 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bleomycin Sulfate
Study NCT00002524 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Study NCT00002524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Study NCT00002524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study NCT00002524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Study NCT00002524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride (DOX)
Study NCT00002524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Study NCT00002524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Study NCT00002524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Study NCT00002524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin calcium
Study NCT00002524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Study NCT00002524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Study NCT00002524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentamidine
Study NCT01835158 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunitinib Malate
Description: Given PO
Study NCT00584519 — intervention group
Intervention type: OTHER
Intervention: non-interventional
Description: non-interventional
Study NCT02655549 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Px563L, RPA563, or placebo
Description: Two intramuscular injections
Study NCT02542826 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation
Description: Patients will participate in 3 exercise training sessions/wk for a period of 7-12 wks at one of 4 sites in Quebec. Each training session will include 30-45 min of aerobic training (cycling and/or treadmill walking) at a target intensity of 80% of the maximal heart rate achieved during a symptom-limited incremental cycle exercise test performed prior to the pulmonary rehabilitation program; and 20-30 min of strength training exercises.
Study NCT01383226 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Thoracic endosonography
Description: Thoracic endosonography is a minimal invasive diagnostic intervention
Study NCT03016065 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pea Fiber
Description: Baked goods (2 snacks) with fiber-fortified with 5 g/snack of ground pea hulls
Study NCT03016065 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Baked goods (2 snacks) without added fiber
Study NCT02037334 — intervention group
Intervention type: DEVICE
Intervention: Pregnolia System
Description: No intervention is done except for measuring the stiffness of the cervix in pregnant women
Study NCT00837070 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous zygapophyseal cyst rupture
Description: Patients will be treated by introducing a 20G spinal needle in the inferior joint recess of the zygapophyseal joint.1 ml of celestone-chronodose,1 ml of Marcain 5 mg/ml and 1-3 ml of contrast media:Omnipaque 240 will be injected until the cyst ruptures.
Study NCT00653588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: 40mg
Study NCT00653588 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: 80mg
Study NCT01987440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lubricating gel
Study NCT01987440 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: lubricating gel
Study NCT00626353 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based rehabilitation
Description: Rehabilitation at home during hospital stay and after discharge
Study NCT00626353 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Standard care during hospital stay and in the municipality after discharge
Study NCT03143790 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal Shockwave Terapy
Description: Intervention is treatment with ESWT. Placebo treatment is using the same device as the active treatment, but the shock waves stopped in a non pressure-conductive filter
Study NCT03143790 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Extracorporeal Shockwave Terapy
Description: Intervention is treatment with ESWT. Placebo treatment is using the same device as the active treatment, but the shock waves stopped in a non pressure-conductive filter
Study NCT03773432 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Probe meal
Description: The probe meal will be administered either in the afternoon (conventional schedule) or in the morning (unconventional schedule).
Study NCT02386085 — intervention group
Intervention type: PROCEDURE
Intervention: Osteopathic manipulative treatment (OMT)
Description: OMT will be provided as part of the patient's health care, prior to enrollment in the study. All participants would have received the same intervention (OMT) if they had not enrolled in the study.
Study NCT02049684 — intervention group
Intervention type: PROCEDURE
Intervention: Patch
Study NCT01557439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levocetirizine Dihydrochloride 5 mg Tablets
Description: A single oral dose of Levocetirizine Dihydrochloride 5 mg Tablets